Carnegie Capital Asset Management LLC Makes New $201,000 Investment in GSK plc (NYSE:GSK)

Carnegie Capital Asset Management LLC acquired a new stake in shares of GSK plc (NYSE:GSK) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund acquired 5,419 shares of the pharmaceutical company’s stock, valued at approximately $201,000.

Other large investors have also made changes to their positions in the company. Callahan Advisors LLC acquired a new stake in GSK during the 3rd quarter worth about $1,119,000. Horizon Bancorp Inc. IN raised its position in GSK by 8.9% during the fourth quarter. Horizon Bancorp Inc. IN now owns 3,961 shares of the pharmaceutical company’s stock valued at $147,000 after acquiring an additional 323 shares in the last quarter. Avantax Advisory Services Inc. lifted its holdings in GSK by 23.6% in the third quarter. Avantax Advisory Services Inc. now owns 76,840 shares of the pharmaceutical company’s stock valued at $2,785,000 after acquiring an additional 14,689 shares during the period. International Assets Investment Management LLC purchased a new stake in GSK in the 4th quarter worth approximately $7,024,000. Finally, Cerity Partners LLC grew its stake in shares of GSK by 305.7% during the 4th quarter. Cerity Partners LLC now owns 118,233 shares of the pharmaceutical company’s stock worth $4,383,000 after purchasing an additional 89,089 shares during the period. 15.74% of the stock is owned by hedge funds and other institutional investors.

GSK Stock Down 0.9 %

Shares of GSK opened at $39.60 on Thursday. The stock has a 50 day moving average price of $41.99 and a 200 day moving average price of $38.76. GSK plc has a one year low of $33.33 and a one year high of $43.84. The company has a debt-to-equity ratio of 1.19, a quick ratio of 0.62 and a current ratio of 0.88. The stock has a market capitalization of $82.07 billion, a price-to-earnings ratio of 13.16, a PEG ratio of 1.83 and a beta of 0.64.

GSK (NYSE:GSK) last posted its quarterly earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.72 earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.04). GSK had a return on equity of 51.45% and a net margin of 16.24%. The business had revenue of $10 billion during the quarter, compared to analysts’ expectations of $9.79 billion. Equities research analysts forecast that GSK plc will post 4.02 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, April 11th. Shareholders of record on Friday, February 23rd were issued a $0.3564 dividend. This is a boost from GSK’s previous quarterly dividend of $0.34. This represents a $1.43 annualized dividend and a yield of 3.60%. The ex-dividend date was Thursday, February 22nd. GSK’s dividend payout ratio is presently 52.82%.

Analysts Set New Price Targets

Several research firms recently issued reports on GSK. Jefferies Financial Group upgraded shares of GSK from a “hold” rating to a “buy” rating in a research note on Wednesday, January 3rd. Citigroup upgraded GSK from a “neutral” rating to a “buy” rating in a research report on Tuesday, February 13th. Morgan Stanley initiated coverage on GSK in a report on Tuesday, January 23rd. They issued an “equal weight” rating for the company. Finally, Guggenheim raised GSK from a “neutral” rating to a “buy” rating in a report on Monday, March 4th. One research analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy”.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.